

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**[DRG No. 23-0155]**

**Importer of Controlled Substances Registration**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and been granted a registration by the Drug Enforcement Administration (DEA) as an importer of schedule II controlled substance(s).

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as an importer of various basic class(es) of schedule II controlled substance(s). Information on a previously published notice is listed below. No comments or objections were submitted and no requests for a hearing were submitted for this notice.

**Company**  
Nexus Pharmaceuticals, Inc.

**FR Docket**  
88 FR 72793

**Published**  
October 23, 2023

DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic class(es) schedule II controlled substance(s) is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA investigated each of the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, DEA has granted a registration as an importer for schedule II controlled substance(s) to the above listed company.

Dated: 12/11/2023

**Claude Redd,**  
*Acting Deputy Assistant Administrator.*